ClinVar Miner

Submissions for variant NM_001042492.3(NF1):c.6919A>T (p.Lys2307Ter)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV005134674 SCV005759088 pathogenic Neurofibromatosis, type 1 2024-06-25 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Lys2286*) in the NF1 gene. RNA analysis indicates that this premature translational stop signal induces altered splicing and may result in an absent or disrupted protein product. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with NF1-related conditions. Studies have shown that this premature translational stop signal results in skipping of exon 45 and introduces a premature termination codon (Invitae). The resulting mRNA is expected to undergo nonsense-mediated decay. This variant disrupts a region of the NF1 protein in which other variant(s) (p.Pro2261Leu) have been determined to be pathogenic (PMID: 29618358; Invitae; external communication). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.